Deukwoo Kwon

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Professor

UAMS

Also affiliated: Fox Chase Cancer Center (2016); United States Department of Health and Human Services (2009); National Institutes of Health (2008–2016); The University of Texas MD Anderson Cancer Center (2012); University of Miami (2012–2025); The University of Texas at El Paso (2007); University of Zurich (2014); Jackson Memorial Hospital (2016–2021); University of Miami Health System (2018–2021); National Center for Biotechnology Information (2014); National Cancer Institute (2011); Stanford Medicine (2016); National Cancer Institute (2007–2016); Sylvester Comprehensive Cancer Center (2012–2025); Miami VA Healthcare System (2018); Tisch Cancer Institute (2022–2024); Division of Cancer Epidemiology and Genetics (2007–2016); Pusan National University (2016); University of Pennsylvania (2007); Myongji University (2014); Texas A&M University (2007); The University of Texas Health Science Center at Houston (2022–2025); Stanford University (2016); Icahn School of Medicine at Mount Sinai (2022–2026)

41 h-index 353 pubs 5,123 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Deukwoo Kwon's research focuses on cancer treatment and pharmacology, with a particular emphasis on clinical trials and the investigation of novel therapeutic agents. He has published on the efficacy of combinations such as axitinib and pembrolizumab in advanced sarcomas, and pembrolizumab in unresectable hepatocellular carcinoma. His work also extends to exploring the potential of natural compounds, such as Urolithin A, in targeting cancer pathways like PI3K/AKT/mTOR in pancreatic cancer.

Beyond oncology, Kwon's research interests include patient outcomes and quality of life, as evidenced by a study on the impact of diet on inflammation and dysbiosis in ulcerative colitis patients. He has also contributed to the field of radiation safety, with publications on occupational radiation doses in cardiac catheterization and proposed reference levels for patient radiation doses in interventional radiology. His scholarly output includes over 350 publications and a citation count of over 5,000, with an h-index of 41.

Metrics

h-index: 41
Publications: 353
Citations: 5,123

Positions

Professor 2025–present

University of Arkansas for Medical Sciences Biostatistics ORCID
Associate Professor 2022–2025

The University of Texas Health Science Center at Houston Department of Internal Medicine ORCID
Associate Professor 2022

Icahn School of Medicine at Mount Sinai Population Health Science & Policy ORCID
Research Assistant Professor 2019–2022

University of Miami Public Health Sciences ORCID
Scientist 2011–2019

University of Miami Sylvester Comprehensive Cancer Center ORCID

Selected Publications

Examining inpatient chemotherapy utilization among patients with cancer and impact on outcomes (2025)

The Oncologist 2 citations DOI OpenAlex
A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects (2025)

Molecular Therapy 2 citations DOI OpenAlex
Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105 (2024)

Blood 9 citations DOI OpenAlex
Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer (2024)

Cancer Research 4 citations DOI OpenAlex
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD (2024)

Blood Advances 17 citations DOI OpenAlex
A Smart Water Bottle and Companion App (HidrateSpark 3) to Improve Bladder-Filling Compliance in Patients With Prostate Cancer Receiving Radiotherapy: Nonrandomized Trial of Feasibility and Acceptability (2024)

JMIR Cancer 1 citation DOI OpenAlex
Power calculation for detecting interaction effect in cross-sectional stepped-wedge cluster randomized trials: an important tool for disparity research (2024)

BMC Medical Research Methodology 1 citation DOI OpenAlex
Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancers (2024)

American Journal of Clinical Pathology 3 citations DOI OpenAlex
A Day 14 Endpoint for Acute GVHD Clinical Trials (2024)

Transplantation and Cellular Therapy 11 citations DOI OpenAlex
A Multi-institutional Analysis of Factors Influencing the Rate of Positive MRI Biopsy Among Women with Early-Stage Breast Cancer (2024)

Annals of Surgical Oncology 5 citations DOI OpenAlex
Frequentist model averaging for analysis of dose–response in epidemiologic studies with complex exposure uncertainty (2023)

PLoS ONE 7 citations DOI OpenAlex
Predicting response to immunotherapy in non-small cell lung cancer- from bench to bedside (2023)

Frontiers in Oncology 10 citations DOI OpenAlex
Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI (2023)

Cancers 5 citations DOI OpenAlex
Medication Reconciliation during Transitions of Care Across Institutions: A Quantitative Analysis of Challenges and Opportunities (2023)

Applied Clinical Informatics 6 citations DOI OpenAlex
Impact of Neighborhood Disadvantage on Tumor Biology and Breast Cancer Survival (2023)

Annals of Surgery 12 citations DOI OpenAlex